SCHEMBL16184700

SCHEMBL16184700

COc1cc(-c2ccccc2F)cc2c(N3CCN(C(C)=O)CC3)nc(-c3cccnc3)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 4/20 0.47
▸ MAPT P10636 4/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ GAA P10253 1/20 0.44
▸ LMNA P02545 4/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ CYP11B1 P15538 2/20 0.43
▸ CYP11B2 P19099 1/20 0.43
▸ CYP1A2 P05177 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ CYP2D6 P10635 2/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ CLK4 Q9HAZ1 2/20 0.42
▸ TGFBR1 P36897 1/20 0.41
▸ ACVR1 Q04771 1/20 0.41
▸ CYP17A1 P05093 1/20 0.41
▸ CYP21A2 P08686 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ TACR3 P29371 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184754 0.94 GBA1 (0.44) GBA1MAPTALDH1A1GAALMNA
SCHEMBL16184767 0.92 GBA1 (0.44) GBA1MAPTALDH1A1GAALMNA
SCHEMBL16184784 0.92 GBA1 (0.44) GBA1MAPTALDH1A1GAALMNA
SCHEMBL16184800 0.89 CYP11B1 (0.50) GBA1MAPTALDH1A1GAALMNA
SCHEMBL16184698 0.89 CYP1A2 (0.55) GBA1MAPTALDH1A1GAALMNA
SCHEMBL16184053 0.89 MAPT (0.48) GBA1MAPTALDH1A1GAALMNA
SCHEMBL16184690 0.89 ALDH1A1 (0.51) GBA1MAPTALDH1A1GAALMNA
SCHEMBL16184816 0.89 GBA1 (0.46) GBA1MAPTALDH1A1GAALMNA
SCHEMBL16184735 0.88 GBA1 (0.47) GBA1MAPTALDH1A1GAALMNA
SCHEMBL16184695 0.88 ALDH1A1 (0.53) GBA1MAPTALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB GBA1 1316/4885MAPT 509/4885ALDH1A1 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback